## Predictors of Clinical Outcomes among People with HIV and Tuberculosis Symptoms after Rapid Treatment Initiation in Haiti

<sup>1</sup>Aaron RICHTERMAN\*, <sup>2</sup>Nancy DORVIL\*, <sup>2</sup>Vanessa RIVERA, <sup>3</sup>Heejung BANG, <sup>2</sup>Patrice SEVERE, <sup>2</sup>Kerylyne LAVOILE, <sup>2</sup>Samuel PIERRE, <sup>2</sup>Alexandra APOLLON, <sup>2</sup>Emelyne DUMOND, <sup>2</sup>Guyrlaine PIERRE LOUIS FORESTAL, <sup>2,5</sup>Vanessa ROUZIER, <sup>2</sup>Patrice JOSEPH, <sup>4</sup>Pierre-Yves CREMIEUX, <sup>2,5</sup>Jean W PAPE, <sup>6</sup>Serena P KOENIG

\*co-first authors

Keywords: HIV; Rapid Antiretroviral Therapy Initiation; Outcome Predictors; Haiti

Abbreviations: AIDS, acquired Immunodeficiency syndrome; AOR, adjusted odds ratio; ART, antiretroviral therapy; BMI, body mass index; GHESKIO, Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections; HIV, human immunodeficiency virus; IQR, interquartile range; IPW, inverse probability weighting; NIH, National Institutes of Health; OR, odds ratio; WHO, World Health Organization; USD, United States Dollar

Corresponding author: Aaron Richterman; Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA (19104); e-mail: <u>aaron.richterman@pennmedicine.upenn.edu</u>

Alternative corresponding author: Serena Koenig; Brigham and Women's Hospital, 75 Francis Street, Boston, MA, United States of America; <u>skoenig@bwh.harvard.edu</u>

<sup>1</sup> University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America

<sup>2</sup> Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti

<sup>3</sup>University of California, Davis School of Medicine, Davis, California, United States of America

<sup>4</sup>Analysis Group, Boston, Massachusetts, United States of America

<sup>5</sup>Weill Cornell Medical College, New York, New York, United States of America

<sup>6</sup> Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

### 1 ABSTRACT

#### 2 Introduction

3 Few studies have evaluated baseline predictors of clinical outcomes among people with

4 HIV starting antiretroviral therapy (ART) in the modern era of rapid ART initiation.

5 Methods

6 We conducted a secondary analysis of a randomized controlled trial of two rapid

- 7 treatment initiation strategies for people with treatment-naïve HIV and tuberculosis
- 8 symptoms at an urban clinic in Haiti. We used logistic regression models to assess

9 associations between baseline characteristics and (1) retention in care at 48 weeks, (2)

10 HIV viral load suppression at 48 weeks (among participants who underwent viral load

11 testing), and (3) all-cause mortality.

12 Results

13 500 participants were enrolled in the study 11/2017-1/2020. Eighty-eight (18%)

14 participants were diagnosed with tuberculosis, and ART was started in 494 (99%). After

- adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% Cl
- 16 0.10-0.46), dolutegravir initiation (AOR 2.57, 95% CI 1.22-5.43), age (AOR 1.42 per 10-
- 17 year increase, 95% CI 1.01-1.99), and tuberculosis diagnosis (AOR 3.92, 95% CI 1.36-
- 18 11.28) were significantly associated with retention. Age (AOR 1.36, 95% CI 1.05-1.75),
- dolutegravir initiation (AOR 1.75, 95% CI 1.07-2.85), and tuberculosis diagnosis (AOR
- 20 0.50, 95% CI 0.28-0.89) were associated with viral suppression. Higher CD4 cell count
- at enrollment (unadjusted odds ratio [OR] 0.69, 95% CI 0.55-0.87) and anemia (OR
- 4.86, 95% CI 1.71-13.81) were associated with mortality.

## 23 Conclusions

- 24 We identified sociodemographic, treatment-related, clinical, and laboratory-based
- 25 predictors of clinical outcomes. These characteristics may serve as markers of sub-
- 26 populations that could benefit from additional interventions to support treatment success
- 27 after rapid treatment initiation.

### 28 INTRODUCTION

Rapid initiation of antiretroviral therapy (ART) after HIV diagnosis (i.e., within 7 days of 29 30 diagnosis, including same-day start) has been recommended by the World Health Organization (WHO) since 2017.<sup>1</sup> The 2021 WHO guidelines recommend rapid initiation 31 for all people with HIV except for those with concern for meningitis (i.e., secondary to 32 cryptococcus or tuberculosis).<sup>2</sup> This recommendation was based on multiple 33 randomized controlled trials conducted in diverse settings and published over the last 34 decade.<sup>3-9</sup> These trials demonstrated that rapid ART initiation results in improvements in 35 retention in care, viral load suppression, and mortality. There have been two 36 hypothesized mechanisms behind this benefit — first, that logistical burdens are 37 38 minimized; and second, that the more immediate provision of medicine facilitates a sense of hope, optimism, and connection with the health system. While several 39 40 observational studies using real-world data have suggested that rapid ART initiation 41 may be associated with increased risk of loss to follow-up, these findings can largely be attributed to biases inherent to the study design.<sup>10</sup> 42

People with newly diagnosed HIV commonly present with signs or symptoms suggesting tuberculosis.<sup>11</sup> While the 2021 WHO guidelines acknowledged that there is little information available about the risks or benefits of rapid ART initiation among people with HIV and tuberculosis symptoms, they recommended rapid ART initiation while investigating tuberculosis, with close follow-up within seven days to initiate tuberculosis treatment if necessary. Since the publication of these guidelines, our group has demonstrated high rates of ART initiation and retention in care among people with

HIV and tuberculosis symptoms in Haiti who were randomized to either of two rapid
 treatment initiation strategies.<sup>12</sup>

52 While the recently shifting approach in ART initiation timing reflects the clearly apparent benefits associated with a rapid start, this strategy necessitates a shorter window of 53 time to allow for the assessment of clinical or social risk factors for poor outcomes after 54 initiating ART. As a result, a key research priority in the rapid ART initiation era is to 55 identify readily available baseline characteristics associated with subsequent treatment 56 outcomes such as retention in care, viral suppression, and mortality. A better 57 understanding of these predictors may allow for the development of targeted 58 interventions for sub-populations of people starting ART who are vulnerable to poor 59 60 outcomes after rapid treatment initiation. To address this gap in the literature, we evaluated baseline predictors of clinical outcomes in a randomized trial of two rapid 61 treatment initiation strategies for people with HIV and tuberculosis symptoms receiving 62 care in urban Haiti.12 63

#### 64 **METHODS**

### 65 Study Design and Oversight

We conducted a secondary analysis of a previously reported open-label randomized controlled trial of treatment initiation strategies for people with treatment-naïve HIV and tuberculosis symptoms in Haiti (NCT03154320).<sup>12</sup> Our objective in this secondary analysis was to evaluate baseline predictors of (1) retention in care, (2) HIV viral load suppression at 48 weeks, and (3) all-cause mortality. Participants in the trial were randomized 1:1 to either same-day treatment (same-day tuberculosis testing with same-

72 day tuberculosis treatment if diagnosed with tuberculosis; same-day ART if tuberculosis not diagnosed) versus standard care (initiating tuberculosis treatment within seven days 73 and delaying ART to day seven if tuberculosis not diagnosed). For all participants 74 diagnosed with tuberculosis, ART was initiated two weeks after tuberculosis treatment. 75 The trial found no differences by study arm in the primary outcome of retention in care 76 with 48-week HIV-1 RNA <200 copies/mL. Additional details about the treatment 77 strategies and outcomes have previously been reported.<sup>12</sup> The trial was approved by 78 the institutional review boards at the Haitian Group for the Study of Kaposi's Sarcoma 79 and Opportunistic Infections (GHESKIO), Mass General Brigham, Florida International 80 University, and Weill Cornell Medical College. 81

#### 82 Setting

The study was conducted at GHESKIO in Port-au-Prince, the urban, densely populated 83 84 capital of Haiti. During the study there was pervasive and ongoing geopolitical 85 instability, gang violence, and civil unrest in Haiti, with consequent economic instability and hardship. GHESKIO is a Haitian nongovernmental organization and the largest 86 provider of HIV and tuberculosis care in the Caribbean. GHESKIO provides care for 87 approximately 15,000 people with HIV and >2,000 people with tuberculosis annually. 88 The adult HIV prevalence in Haiti is 1.7%, and the annual tuberculosis incidence is 154 89 per 100,000 persons.<sup>13,14</sup> First-line treatment for HIV included co-formulated efavirenz, 90 tenofovir disoproxil fumarate, and lamivudine until December 2018, after which 91 dolutegravir became available and was preferred over efavirenz. During 2019, all 92 93 people with HIV receiving efavirenz-based regimens at GHESKIO were switched to a dolutegravir-based regimen, regardless of viral load. Tuberculosis was treated 94

95	according to standard guidelines, and all participants who were not diagnosed with
96	tuberculosis disease were treated with prophylactic isoniazid. <sup>15</sup> Based on recent clinical
97	trial results, participants with CD4 count <100 cells/mm <sup>3</sup> received azithromycin for five
98	days, and those with CD4 count <100 cells/mm <sup>3</sup> and tuberculosis received prednisone
99	prophylaxis. <sup>16,17</sup> Retention activities at GHESKIO included: reminder phone calls (or
100	home visits for those without phones) prior to visits, and after missed visits; a
101	transportation subsidy of $\sim$ \$1 USD at each visit; and a $\sim$ \$1 USD phone card at each
102	visit.

103 Study Population

We included all participants enrolled in the original trial in this secondary analysis.<sup>12</sup> 104 105 Patients were eligible for inclusion in the trial if they had documented HIV-1 infection, 106 were ≥18 years of age, ART-naïve, and reported cough, fever, and/or night sweats of 107 any duration, and/or weight loss. Exclusion criteria included tuberculosis treatment in 108 the past year, lack of preparedness on an ART readiness questionnaire, pregnancy or 109 breastfeeding, active drug or alcohol use, a mental condition that would interfere with 110 completing study requirements, plans to transfer during the study period, symptoms 111 consistent with WHO stage 4 neurologic disease, or WHO "danger signs" of temperature >39 degrees Celsius, pulse >120 beats/minute, respiratory rate >30 112 breaths/minute, or inability to walk unaided. All participants provided written informed 113 consent. 114

115 *Data* 

Study procedures have been reported in detail elsewhere.<sup>12</sup> For the purposes of this 116 analysis, we included baseline demographic, clinical and laboratory data, as well as 117 outcome data 48 weeks after enrollment, all of which were extracted from the GHESKIO 118 119 electronic health record. Baselines variables included in this analysis were: age, sex, income less than \$1 USD per day (self-report), educational attainment, marital status, 120 body mass index (BMI), CD4 cell count, tuberculosis diagnosis (microbiologically or 121 clinically diagnosed), and study arm (same-day or standard). We also included 122 information about the ART regimen that was initiated. Outcome variables included clinic 123 attendance at 48 weeks, HIV-1 RNA at 48 weeks, and mortality during 48 weeks of 124

125 follow-up.

#### 126 Outcomes

127 We considered three outcomes in this analysis. Retention in care was defined as

128 attending a clinical visit 48 weeks after enrollment (with a prespecified window of +/-

twelve weeks). Viral load suppression was defined as having HIV-1 RNA<200

130 copies/mL 48 weeks after enrollment (with a prespecified window of +/- twelve weeks),

and was evaluated among all participants who had undergone viral load testing within

that window. All-cause mortality over 48 weeks of follow-up after enrollment was

determined using family report (death certificates are not available in Haiti).

134 Statistical Analysis

Baseline characteristics were summarized using medians and interquartile ranges (IQR)
 for continuous variables and frequencies and percentages for categorical/binary
 variables.

We assessed predictors of retention in care, viral suppression, and mortality using 138 logistic regression models. We evaluated associations between our outcome variables 139 and the following baseline predictors: age (continuous variable, per 10 year increase), 140 female sex, income less than \$1 USD per day, less than secondary education, married, 141 undernutrition (BMI<18.5 kg/m<sup>2</sup>), CD4 cell count (continuous variable, per 50 cell/mm<sup>3</sup> 142 increase), anemia (NIH Division of AIDS Grade  $\geq$ 3),<sup>18</sup> tuberculosis diagnosis, and 143 randomization to the standard strategy study arm. Because first-line ART changed from 144 an efavirenz-based regimen to a dolutegravir-based regimen partway through the study, 145 we also included a binary variable indicating whether a participant had been initiated on 146 dolutegravir. We prespecified this set of 11 predictors and cutoffs for binary predictors 147 from clinical perspectives; we did not conduct model-based variable selection. We did 148 not adjust time-varying covariates that may be less relevant for prediction, or variables 149 that can be affected by study treatment/exposure (e.g., symptoms during follow-up). 150

We first evaluated univariable associations between predictors and the three outcomes. We then generated multivariable models for the retention in care and viral load suppression outcomes that included all predictors. We did not build a multivariable model for the mortality outcome because there were few deaths (n=15).

Next, for the viral load suppression outcome, we additionally fitted an inverse probability
of (censoring) weighting regression model to account for potential selection bias
resulting from exclusion of 66 participants who did not undergo viral load testing at week
48.<sup>19,20</sup> To do this, we weighted observations by the inverse probability that a given
participant had a viral load test performed. These probabilities of having non-missing (or

160 complete) data were fitted via multivariable logistic regression that included the 11

<sup>161</sup> baseline covariates in this analysis.<sup>20</sup>

162 We performed statistical analyses using SAS version 9.4 (SAS Institute, Cary, NC,

163 USA).

164 **RESULTS** 

165 Out of 576 people screened for trial participation between November 2017 and January

166 2020, 500 were enrolled and are included in this analysis (Table 1).<sup>12</sup> Median age was

167 37 years (IQR 30 to 45), and 234 (47%) were female. Cough, fever, night sweats, and

weight loss were reported by 200 (47%), 194 (39%), 72 (14%), and 491 (98%)

participants, respectively. Median BMI was 20.6 (IQR: 18.7 to 22.9), and 116 (23%) met

170 criteria for undernutrition. Median hemoglobin was 11.8 g/dL (IQR: 10.1, 11.8), and 81

171 (16%) participants with available hemoglobin results (N=480) had Grade  $\geq$ 3 anemia.<sup>18</sup>

Median CD4 count was 274 cells/mm<sup>3</sup> (IQR 128 to 426), with 101 (20%) having CD4

count <100 cells/mm<sup>3</sup>. Eighty-eight (18%) participants were diagnosed with tuberculosis

at baseline; of these, 68 (77%) were diagnosed microbiologically. All participants with

tuberculosis were started on first-line treatment for drug-susceptible tuberculosis.

Antiretroviral therapy was started in 494 (99%) participants — 407 (83%) who were not diagnosed with tuberculosis at baseline, 69 (14%) who initiated ART after initiating tuberculosis treatment, and 18 (4%) who initiated ART before initiating tuberculosis treatment (e.g., in the context of positive culture after initial negative nucleic acid amplification testing). Among participants who started ART, 310 (62%) initiated an efavirenz-based regimen, and 184 (37%) initiated a dolutegravir-based regimen. Among

182	the 412 participants not diagnosed with tuberculosis at baseline, antiretroviral therapy
183	was initiated in 407 (98.8%) at a median time of 6 (IQR 0 to 7) days — 202 (49%) on
184	the day of HIV diagnosis, 110 (27%) within 7 days, 83 (20%) from 8 to 14 days, and 12
185	(3%) >14 days after HIV diagnosis. Among participants started on efavirenz, 158 (51%)
186	were transitioned to dolutegravir during the study period, a median of 245 days (IQR
187	201 to 289) after starting ART. Nine participants (2%) who were started on an efavirenz-
188	based regimen were switched to a second-line protease inhibitor-based regimen during
189	the study period.
190	There were 447 (89%) participants retained in care at week 48, among whom 431
191	(96%) underwent viral load testing. Among participants who underwent viral load
192	testing, 320 (72%) had HIV-1 RNA <200 copies/mL. Fifteen (3%) participants died
193	during the study period, with causes of death previously reported. <sup>12</sup>
192	during the study period, with causes of death previously reported.
192	during the study period, with causes of death previously reported.
195	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI
194	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI
194 195	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were
194 195 196	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were significantly associated with retention in care at 48 weeks (Table 2). After multivariable
194 195 196 197	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were significantly associated with retention in care at 48 weeks (Table 2). After multivariable adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI
194 195 196 197 198	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were significantly associated with retention in care at 48 weeks (Table 2). After multivariable adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI 0.10 to 0.46) remained significantly associated with a reduced odds of retention in care.
194 195 196 197 198 199	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were significantly associated with retention in care at 48 weeks (Table 2). After multivariable adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI 0.10 to 0.46) remained significantly associated with a reduced odds of retention in care. Dolutegravir initiation (AOR 2.57, 95% CI 1.22 to 5.43), age (AOR 1.42 per 10 year
194 195 196 197 198 199 200	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were significantly associated with retention in care at 48 weeks (Table 2). After multivariable adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI 0.10 to 0.46) remained significantly associated with a reduced odds of retention in care. Dolutegravir initiation (AOR 2.57, 95% CI 1.22 to 5.43), age (AOR 1.42 per 10 year increase, 95% CI 1.01 to 1.99), and tuberculosis diagnosis at enrollment (AOR 3.92,
194 195 196 197 198 199 200	In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were significantly associated with retention in care at 48 weeks (Table 2). After multivariable adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI 0.10 to 0.46) remained significantly associated with a reduced odds of retention in care. Dolutegravir initiation (AOR 2.57, 95% CI 1.22 to 5.43), age (AOR 1.42 per 10 year increase, 95% CI 1.01 to 1.99), and tuberculosis diagnosis at enrollment (AOR 3.92,

204	0.69), and dolutegravir initiation (OR 1.81, 95% CI 1.13 to 2.90) were significantly
205	associated with viral suppression (Table 3). After multivariable adjustment, age (AOR
206	1.36, 95% CI 1.05 to 1.75) and dolutegravir initiation (AOR 1.75, 95% CI 1.07 to 2.85)
207	remained positively associated with viral suppression, and tuberculosis diagnosis (AOR
208	0.50, 95% CI 0.28 to 0.89) remained negatively associated with viral suppression.
209	Findings were similar after incorporating inverse probability weights to account for
210	participants who did not undergo viral load testing (Table 3). Weights ranged from 1.02
211	to 1.48, which means 1 complete case/person represented approximately 1 to 1.5
212	persons/observations from the overall population.
213	Higher CD4 cell count at enrollment was significantly associated with a lower odds of

214 mortality in unadjusted models (OR 0.69, 95% CI 0.55 to 0.87) (Table 4). Grade ≥3

anemia was associated with a significantly greater odds of mortality (OR 4.86, 95% CI

216 **1.71 to 13.81**).

#### 217 **DISCUSSION**

218 In this study of 500 people with newly diagnosed HIV and tuberculosis symptoms (about 219 one in five of whom were diagnosed with tuberculosis) who participated in a randomized trial of two rapid treatment initiation protocols, we identified sociodemographic (age, 220 221 educational attainment), treatment-related (dolutegravir-based regimens), clinical 222 (tuberculosis diagnosis), and laboratory-based (CD4 count and anemia) predictors of clinical outcomes over a follow-up period of 48 weeks. Despite substantial geopolitical 223 instability in Haiti during the study period, nearly all participants initiated ART (over three 224 quarters of participants without tuberculosis started within 7 days) and retention in care 225

was high. This is one of the first studies to report baseline predictors of clinical
outcomes in the context of rapid ART initiation, especially among people experiencing
tuberculosis symptoms. The predictors we identified can be easily and quickly
measured during the condensed evaluation prior to rapid ART initiation, and may serve
as markers of sub-populations that could benefit from additional interventions to support
treatment success.

The two sociodemographic factors associated with poorer outcomes were younger age (associated with lower retention in care and lower viral suppression rates) and less than a secondary education (associated with lower retention in care). Both of these factors have previously been identified as predictors of clinical outcomes in pre-rapid ART initiation settings,<sup>21</sup> and our findings demonstrate that they continue to be important markers in the current era.

Education was the baseline characteristic most strongly associated with retention in 238 239 care. Education was also identified as a key driver of persistent disparities in life expectancy among patients initiating ART at GHESKIO during earlier time periods.<sup>22</sup> 240 Our results may reflect several potential mechanisms. First, lower education may have 241 been associated with lower health literacy, with greater consequent difficulty 242 communicating the benefits of ART and clinical follow-up. If this is the case, patients 243 244 with lower education levels may benefit from tools designed to facilitate effective and rapid communication of key HIV-related concepts.<sup>23,24</sup> While this may be exacerbated 245 by the shorter duration of pre-treatment counseling inherent to rapid ART initiation, as 246 247 we noted above this association was also described prior to the adoption of rapid ART initiation.<sup>21</sup> Second, this association may result from an unmeasured social or economic 248

factor that is correlated with education. For example, food insecurity tends to be strongly
associated with educational attainment, is highly prevalent in Haiti, and has been
associated with a wide variety of adverse HIV outcomes.<sup>25-28</sup> More generally,
socioeconomic factors like poverty are associated with education and can strongly
influence HIV outcomes.<sup>29</sup> While future research should aim to disentangle these
potential mechanisms, educational level can be used in HIV programs as a prognostic
marker for clinical outcomes after treatment initiation.

256 Initiation of a dolutegravir-based regimen (versus an efavirenz-based regimen) was associated with an increased odds of both retention in care and viral suppression. This 257 finding further supports the preference for dolutegravir as first-line therapy,<sup>2</sup> is 258 259 consistent with dolutegravir's greater tolerability and effectiveness relative to efavirenz,<sup>30</sup> and illustrates the instrumental role that dolutegravir can play in improving 260 HIV-related population health. This is especially the case in settings with high rates of 261 efavirenz resistance among ART-naïve people with HIV, like Haiti.<sup>31</sup> Of note, about half 262 263 the participants started on a efavirenz-based ART were transitioned to dolutegravir at 264 some point during the study period. This likely biased the association between 265 dolutegravir initiation and clinical outcomes towards the null, meaning that the benefits 266 of dolutegravir are likely to be even greater than those estimated in this study.

While all participants in this study were experiencing tuberculosis symptoms at enrollment, only 18% were ultimately diagnosed with tuberculosis, and being diagnosed with tuberculosis was significantly associated with greater odds of retention in care and lower odds of viral suppression. Greater retention likely results from closer clinical contact during tuberculosis treatment (e.g., directly observed therapy) and the fact that

272 people with tuberculosis commonly experience rapid improvement in symptoms on therapy. Other studies have also reported an association between virologic failure and 273 tuberculosis co-infection.<sup>32-35</sup> Lower odds of viral suppression after tuberculosis 274 275 diagnosis may relate to delays in ART initiation (although these tended to be short), 276 difficulty with drug tolerability given additional medications being administered. 277 Tuberculosis may also increase HIV viral load and the size of the HIV reservoir. 278 There were few deaths among participants during follow-up, and two baseline 279 laboratory characteristics were significantly associated with death — CD4 cell count and anemia. Immunologic dysfunction from progressive HIV has long been recognized as a 280 key risk factor for death among people with HIV. Anemia, which may result from both 281 282 nutritional and non-nutritional (e.g., disseminated infection) mechanisms, has also been identified as an important risk factor for mortality.<sup>36,37</sup> 283

284 This study had several limitations. It was conducted among participants reporting 285 tuberculosis symptoms at a single large urban clinic with a high quality of care, which may limit generalizability to other settings and contexts. Our viral suppression outcome 286 was assessed among participants who completed viral load testing at week 48, which 287 raises the possibility of selection bias. However, over 85% of participants underwent 288 289 viral load testing, and estimates from our missing data-adjusted analyses were nearly 290 identical to those from an unweighted multivariable model. Lastly, the odds ratios reported here are associational, not casual, with non-randomized exposures, which is 291 typical in studies of identification of predictors or risk or protective factors. 292

### 293 CONCLUSIONS

294 In this study of 500 people with newly diagnosed HIV and tuberculosis symptoms (18%) of whom were diagnosed with tuberculosis) who participated in a trial of two rapid 295 treatment initiation protocols, we identified sociodemographic (age, educational 296 297 attainment), treatment-related (dolutegravir-based regimens), clinical (tuberculosis diagnosis), and laboratory-based (CD4 count and anemia) predictors of clinical 298 outcomes over a follow-up period of 48 weeks. This is one of the first studies to report 299 baseline predictors of clinical outcomes in the context of rapid ART initiation, especially 300 among people reporting tuberculosis symptoms. The predictors we identified can be 301 easily and quickly assessed during the condensed evaluation prior to rapid ART 302 initiation, and may serve as markers of sub-populations that could benefit from 303 304 additional interventions to support treatment success.

### 305 **DECLARATIONS**

306 All authors declare no conflicts of interest.

#### 307 FUNDING

308 This study was funded by a grant from the National Institute of Allergy and Infectious

Diseases (R01AI131998; primary investigator: SK). The funders had no role in study

design, data collection and analysis, decision to publish, or preparation of the

311 manuscript.

### 312 **REFERENCES**

- 3131.World Health Organization Guidelines Review Committee. Guidelines for managing advanced314HIV disease and rapid initiation of antiretroviral therapy. Geneva, Switzerland: World Health315Organization;2017.
- World Health Organization. *Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach.* Geneva, Switzerland: World Health Organization;2021.
- 319 3. Labhardt ND, Ringera I, Lejone TI, et al. Effect of Offering Same-Day ART vs Usual Health Facility 320 Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults 321 With HIV in Lesotho: The CASCADE Randomized Clinical Trial. Jama. 2018;319(11):1103-1112.
- 3224.Rosen S, Maskew M, Larson BA, et al. Simplified clinical algorithm for identifying patients eligible323for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in324South Africa and Kenya. PLOS Medicine. 2019;16(9):e1002912.
- 3255.Amanyire G, Semitala FC, Namusobya J, et al. Effects of a multicomponent intervention to326streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised327trial. The Lancet HIV. 2016;3(11):e539-e548.
- 3286.Stevens WS, Gous NM, MacLeod WB, et al. Multidisciplinary Point-of-Care Testing in South329African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention330in Care. Journal of acquired immune deficiency syndromes (1999). 2017;76(1):65-73.
- Koenig SP, Dorvil N, Dévieux JG, et al. Same-day HIV testing with initiation of antiretroviral
  therapy versus standard care for persons living with HIV: A randomized unblinded trial. *PLoS Med.* 2017;14(7):e1002357.
- 8. Rosen S, Maskew M, Fox MP, et al. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. *PLoS Med.* 2016;13(5):e1002015.
- Maskew M, Brennan AT, Fox MP, et al. A clinical algorithm for same-day HIV treatment initiation
  in settings with high TB symptom prevalence in South Africa: The SLATE II individually
  randomized clinical trial. *PLOS Medicine*. 2020;17(8):e1003226.
- Labhardt ND, Brown JA, Sass N, Ford N, Rosen S. Treatment Outcomes After Offering Same-Day
  Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies
  Between Different Studies. *Clinical Infectious Diseases*. 2023;77(8):1176-1184.
- Burke RM, Rickman HM, Singh V, et al. Same-day antiretroviral therapy initiation for people
  living with HIV who have tuberculosis symptoms: a systematic review. *HIV medicine*.
  2022;23(1):4-15.
- 34512.Dorvil N, Rivera VR, Riviere C, et al. Same-day testing with initiation of antiretroviral therapy or346tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms347at HIV diagnosis: A randomized open-label trial from Haiti. *PLoS Med.* 2023;20(6):e1004246.
- 348 13. Global Tuberculosis Program, World Health Organization, Country Profile. Haiti.
   349 <u>https://worldhealthorg.shinyapps.io/tb\_profiles/?\_inputs\_&entity\_type=%22country%22&iso2=</u>
   350 <u>%22HT%22&lan=%22EN%22</u>. Published 2024. Accessed May 10, 2024.
- 351 14. UNAIDS Country Fact Sheets. Haiti 2022.
   352 <u>https://www.unaids.org/en/regionscountries/countries/haiti</u>. Accessed May 10, 2024.
   353 15. World Health Organization Operation Handbook on Tuberculosis, Module 4: Treatment Drug-
- 354Susceptible Tuberculosis Treatment. <a href="https://www.who.int/publications/i/item/9789240050761">https://www.who.int/publications/i/item/9789240050761</a>.355Published 2022. Accessed May 13, 2024.
- 16. Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the Prevention of Paradoxical
- Tuberculosis-Associated IRIS. *New England Journal of Medicine*. 2018;379(20):1915-1925.

358	17.	Hakim J, Musiime V, Szubert AJ, et al. Enhanced Prophylaxis plus Antiretroviral Therapy for
359		Advanced HIV Infection in Africa. <i>New England Journal of Medicine</i> . 2017;377(3):233-245.
360	18.	Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events.
361		Corrected Version 2.1. July 2017. Accessed on Apirl 12, 2024 at:
362		https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.
363	19.	Hernán M, Robins J. Chapter 12: IP Weighting and Marginal Structural Models. In: Causal
364		Inference: What If. Boca Raton: Chapman & Hall/CTC; 2020.
365	20.	Bang H, Spiegelman D. Estimating treatment effects in studies of perinatal transmission of HIV.
366		Biostatistics. 2004;5(1):31-43.
367	21.	Bulsara SM, Wainberg ML, Newton-John TRO. Predictors of Adult Retention in HIV Care: A
368		Systematic Review. AIDS and Behavior. 2018;22(3):752-764.
369	22.	Smiley CL, Rebeiro PF, Cesar C, et al. Estimated life expectancy gains with antiretroviral therapy
370		among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort
371		study. The Lancet HIV. 2021;8(5):e266-e273.
372	23.	Richterman A, Klaiman T, Palma D, et al. B-OK: A Visual and Tactile Tool for HIV Treatment
373	23.	Adherence Support in a United States Urban Center. <i>medRxiv.</i> 2024:2024.2002.2028.24303498.
374	24.	Govathson C, Ndlovu N, Rambally-Greener L, et al. Increasing HIV treatment literacy among
375	27.	people living with HIV using a novel health communication aid: Evidence from KwaZulu Natal
376		province, South Africa. In: Cold Spring Harbor Laboratory; 2023.
377	25.	Chop E, Duggaraju A, Malley A, et al. Food insecurity, sexual risk behavior, and adherence to
378	25.	antiretroviral therapy among women living with HIV: A systematic review. <i>Health Care Women</i>
379		Int. 2017;38(9):927-944.
	26	
380	26.	Singer AW, Weiser SD, McCoy SI. Does Food Insecurity Undermine Adherence to Antiretroviral
381	27	Therapy? A Systematic Review. <i>AIDS Behav.</i> 2015;19(8):1510-1526.
382	27.	Aibibula W, Cox J, Hamelin A-M, McLinden T, Klein MB, Brassard P. Association Between Food
383		Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis. AIDS and Belenview 2017, 21(2), 754, 765
384	20	Behavior. 2017;21(3):754-765.
385	28.	Aibibula W, Cox J, Hamelin AM, Mamiya H, Klein MB, Brassard P. Food insecurity and low CD4
386		count among HIV-infected people: a systematic review and meta-analysis. <i>AIDS care.</i>
387		2016;28(12):1577-1585.
388	29.	Richterman A, Leandre F, Jerome JG, Tsai AC, Ivers LC. Mortality Over Long-term Follow-up for
389		People With HIV Receiving Longitudinal Care and Antiretroviral Therapy in Rural Haiti. Open
390		Forum Infect Dis. 2020;7(8):ofaa328.
391	30.	Kanters S, Park JJ, Chan K, et al. Interventions to improve adherence to antiretroviral therapy: a
392		systematic review and network meta-analysis. <i>The lancet HIV</i> . 2017;4(1):e31-e40.
393	31.	Koenig S, Wu J, Pierre S. Abstract PEB0258: HIV drug resistance (HIVDR) in Haiti: Impact on
394		future guidelines. AIDS 2020 virtual meeting; 2020.
395	32.	Telele NF, Kalu AW, Marrone G, et al. Baseline predictors of antiretroviral treatment failure and
396		lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PloS one.
397		2018;13(7):e0200505.
398	33.	Demsie DG, Bantie AT, Allene MD, Alema NM, Gebrie D. Antiretroviral treatment failure among
399		HIV-positive adults taking first-line therapy and associated risk factors at Adigrat General
400		hospital, Adigart, Ethiopia 2019: A cross sectional study. International Journal of Surgery Open.
401		2020;26.
402	34.	Von Braun A, Sekaggya-Wiltshire C, Scherrer AU, et al. Early virological failure and HIV drug
403		resistance in Ugandan adults co-infected with tuberculosis. AIDS Research and Therapy.
404		2017;14(1).

- 35. Bezabih YM, Beyene F, Bezabhe WM. Factors associated with first-line antiretroviral treatment
  failure in adult HIV-positive patients: a case-control study from Ethiopia. *BMC infectious diseases.* 2019;19(1).
- 40836.Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy409(ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. *PloS*410one. 2011;6(12):e28691.
- 411 37. Raynell Lang, Sally B.Coburn, M. John Gill, et al. Abstract 688: Association of Anemia on Survival
  412 among People with HIV after ART Initiation. Conference on Retrovirology and Opportunistic
  413 Infections (CROI) 2023; 2023; Seattle, Washington.

## 415 **Table 1. Baseline Characteristics of Study Participants.** Data are presented as N(%)

416 unless otherwise specified; N=500 unless otherwise specified.

Characteristics	N (%), unless otherwise specified
Age at enrollment (years), median (IQR)	37 (30-45)
Female	234 (47)
Income <\$1 USD per day	372 (74)
Less than secondary education	192 (38)
Married	261 (52)
Body mass index (kg/m <sup>2</sup> ), median (IQR)	20.6 (18.7-22.9)
Undernutrition (Body mass index <18.5)	116 (23)
CD4 count (cells/mm <sup>3</sup> ), median (IQR) (N=495)	274 (128-426)
Hemoglobin (g/dl), median (IQR) (N=480)	11.8 (10.1-13.4)
Anemia (NIH Division of AIDS classification	81 (16)
Grade ≥3)* (N=480)	
Diagnosed with TB at enrollment	88 (18)
Initiated on dolutegravir-based ART (vs.	184 (37%)
efavirenz), among ART initiators (N=494)	
Randomized to standard group	250 (50%)

417

\*NIH DAIDS threshold for anemia of Grade  $\geq$ 3 severity is hemoglobin value  $\geq$ 9g/dL for

419 males and  $\geq 8.5$  g/dL for females.

# 420 **Table 2. Baseline Predictors of Retention in Care at 48 Weeks (N=500)**

	Univariable Regression		Multivariable Regression**		
Predictors	OR (95% CI)	p-value	OR (95% CI)	p-value	
Age (per 10 year increase)	1.19 (0.88, 1.61)	0.25	1.42 (1.01, 1.99)	0.04	
Female sex	0.98 (0.56, 1.74)	0.95	1.28 (0.67, 2.43)	0.46	
Income <\$1 USD per day	0.84 (0.42, 1.64)	0.60	0.80 (0.37, 1.70)	0.55	
Less than secondary education	0.34 (0.17, 0.66)	0.001	0.21 (0.10, 0.46)	<.0001	
Married	0.82 (0.46, 1.46)	0.50	0.72 (0.38, 1.35)	0.30	
Undernutrition	1.04 (0.53, 2.04)	0.92	0.97 (0.46, 2.05)	0.93	
CD4 count at enrollment (per 50 cells/mm <sup>3</sup>	1.01 (0.95, 1.08)	0.67	1.04 (0.97, 1.10)	0.30	
increase)					
Anemia (Grade ≥3)*	0.81 (0.39, 1.69)	0.58	0.51 (0.23, 1.16)	0.11	
Diagnosed with tuberculosis at enrollment	2.19 (0.85, 5.67)	0.11	3.92 (1.36,	0.01	
			11.28)		
Randomized to standard group (vs. same-	1.60 (0.90, 2.87)	0.11	1.73 (0.93, 3.25)	0.09	
day group)					
Dolutegravir-based ART	2.74 (1.34, 5.60)	0.006	2.57 (1.22, 5.43)	0.01	

\*NIH DAIDS threshold for anemia of Grade  $\geq$ 3 severity is hemoglobin value  $\geq$ 9g/dL for males and  $\geq$ 8.5 g/dL for females.

422 \*\* Missing data were present in 5 persons. AUC=0.75.

## Table 3. Baseline Predictors of Viral Suppression among Patients who Completed 48-week HIV-1 RNA Testing

	Univariable Analysis		Multivariable Analysis		Multivariable Analysis with	
Predictors	(N=431)		(N=429)**		Inverse Probability Weights	
					(N=429)***	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Age (per 10 year increase)	1.35 (1.08, 1.71)	0.01	1.36 (1.05, 1.75)	0.02	1.35 (1.07, 1.70)	0.01
Female sex	1.05 (0.68, 1.62)	0.82	1.05 (0.66, 1.67)	0.84	1.05 (0.68, 1.62)	0.83
Income <\$1 USD per day	0.90 (0.55, 1.49)	0.69	1.11 (0.64, 1.90)	0.72	1.10 (0.66, 1.82)	0.72
Less than secondary education	0.89 (0.57, 1.37)	0.58	0.78 (0.48, 1.27)	0.32	0.79 (0.50, 1.23)	0.29
Married	1.44 (0.93, 2.22)	0.10	1.42 (0.90, 2.26)	0.14	1.49 (0.97, 2.29)	0.07
Undernutrition	0.70 (0.43, 1.14)	0.15	0.89 (0.25, 1.54)	0.68	0.87 (0.52, 1.44)	0.58
CD4 count at enrollment (per 50 cells/mm <sup>3</sup>	1.04 (0.99, 1.09)	0.16	1.03 (0.98, 1.08)	0.31	1.03 (0.98, 1.08)	0.28
increase)						
Anemia (Grade ≥3)*	0.82 (0.46, 1.46)	0.50	1.07 (0.57, 2.01)	0.83	1.05 (0.58, 1.90)	0.87
Diagnosed with tuberculosis at enrollment	0.42 (0.25, 0.69)	0.0008	0.50 (0.28, 0.89)	0.02	0.50 (0.29, 0.86)	0.01
Randomized to standard group (vs. same-	1.25 (0.81, 1.93)	0.31	1.15 (0.73, 1.81)	0.54	1.11 (0.73, 1.69)	0.63
day group)						
Dolutegravir-based ART	1.81 (1.13, 2.90)	0.01	1.75 (1.07, 2.85)	0.03	1.72 (1.09, 2.72)	0.02

\*NIH DAIDS threshold for anemia of Grade  $\geq$ 3 severity is hemoglobin value  $\geq$ 9g/dL for males and  $\geq$ 8.5 g/dL for females

<sup>425</sup> \*\* Missing data were present in 2 persons. AUC=0.66.

426 \*\*\* Missing data were present in 2 persons. AUC=0.66. CIs were estimated assuming weight is known since very similar

427 CIs were obtained when weight is known or estimated.

## 430 Table 4. Baseline Predictors of Mortality

	Univariable Analysis*		
Predictors	OR (95% CI)	p-value	
Age (per 10 year increase)	1.25 (0.76, 2.06)	0.38	
Female sex	0.99 (0.36, 2.79)	0.99	
Income <\$1 USD per day	0.50 (0.18, 1.45)	0.20	
Less than secondary education	1.59 (0.54, 4.73)	0.40	
Married	0.60 (0.21, 1.72)	0.34	
Undernutrition	1.69 (0.56, 5.03)	0.35	
CD4 count at enrollment (per 50 cells/mm <sup>3</sup>	0.69 (0.55, 0.87)	0.002	
increase)			
Grade ≥3 anemia*	4.86 (1.71, 13.81)	0.003	
Diagnosed with tuberculosis at enrollment	0.33 (0.04, 2.52)	0.28	
Randomized to standard group (vs. same-	0.66 (0.23, 1.88)	0.43	
day group)			
Initiated on dolutegravir-based ART	0.62 (0.19, 1.96)	0.41	

<sup>431</sup> \*We did not conduct Multivariable regression due to only 15 deaths.